Nordic Nanovector appoints Tone Kvåle as Interim Chief Executive Officer
Oslo, Norway, 20 April 2018
Nordic Nanovector ASA (OSE: NANO) announces that it has appointed Tone Kvåle to
the position of Interim Chief Executive Officer (CEO) in addition to her current
role as Chief Financial Officer. The appointment is made to conform to Norwegian
Companies Law. A search for a full-time CEO is progressing.
-End-
For further information, please contact:
Ludvik Sandnes, Chairman
Cell: +47 907 43017
Email: [email protected]
Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: [email protected]
Media Enquiries
Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: [email protected]
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers. Nordic Nanovector’s lead clinical-stage candidate is
Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC)
https://newsweb.oslobors.no/message/449279